Navigation Links
OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
Date:7/14/2008

VANCOUVER, July 14 /PRNewswire/ - OncoGenex Technologies Inc. announced today that the company has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase 3 registration trial of OGX-011, its lead product candidate targeting hormone refractory prostate cancer, via the Special Protocol Assessment (SPA) process. In the letter responding to the OncoGenex submission, the FDA stated that they agreed with the design and planned analysis proposed by OncoGenex, and that the study design adequately addresses the objectives necessary to support a regulatory submission.

The Phase 3 trial has been designed in collaboration with internationally recognized experts in the treatment of patients with hormone-refractory prostate cancer (HRPC) including Dr. Celestia Higano at the University of Washington and Dr. Kim Chi at the University of British Columbia. This will be a randomized, controlled, international study in 765 men with metastatic HRPC who responded to first-line docetaxel therapy, but subsequently progressed and are in need of second-line chemotherapy. Patients will be randomized to receive treatment with either OGX-011 and docetaxel/prednisone or docetaxel/prednisone alone. The primary endpoint of the study will be overall survival. It is expected that approximately 80 sites in the United States and Canada will participate in this study.

"Patients who have progressed after receiving docetaxel as first-line chemotherapy have few options," said Cindy Jacobs, M.D., Ph.D., OncoGenex' Executive Vice-President and Chief Medical Officer. "A recent survey of 130 oncologists practicing in Canada and the United States indicates that their primary option for patients who responded to first-line docetaxel is retreatment with docetaxel. This is not surprising since the only product shown to increase survival in patients with HRPC is docetaxel."

Dr. Jacobs added, "Preliminary data from Phase 2 studies of OGX-011 in com
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex increases economic interest in lead cancer drug OGX-011
2. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
3. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
4. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
5. CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
6. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
7. Edison Pharmaceuticals Receives Commendation From the City of San Jose
8. GeneraMedix Inc. Receives Approval for Epoprostenol for Injection 1.5 mg
9. Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems
10. Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
11. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... California (PRWEB) March 04, 2015 ... (PCR) represents one of the fastest growing technologies in ... biologists in subcellular visualization is driving growth in nucleic ... for deeper understanding of gene expressions will continue to ... Expanding applications in fields ranging from pharma, biotech, food ...
(Date:3/4/2015)... 2015 Lancée par ... en décembre 2011, l,étude collaborative française ... qui compare   l es microsphères en ... dans le carcinome hépatocellulaire avancé, a recruté plus ... avancé   ; les résultats sont attendus fin ...
(Date:3/3/2015)... /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), ... that target the underlying mechanisms of cancer, today reported ... December 31, 2014. Effective July 17, 2014, ... 31 to December 31. As a result of that ... the quarter and the seven months ended December 31, ...
(Date:3/3/2015)... , March 3, 2015 NASA astronaut Scott ... this month to spend a year living and working on ... interviews from 5:30 to 7 a.m. EDT Monday, March 9. ... as he completes the final weeks of his training. ... video on NASA Television highlighting his mission training and previous ...
Breaking Biology Technology:Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2
... ... SINGAPORE , January 22 , ... in the Region Together for Honors , Elsevier announced ... its flagship product Scopus(R), the,world,s largest abstract and citation database of peer-reviewed literature,and ...
... Boston, Mass. A combination of two fully human monoclonal ... Massachusetts Medical School (UMMS) and Medarex, a wholly owned ... standard antibiotics, was shown to reduce recurrence of a ... enrolled in a Phase 2 clinical trial. The results ...
... , Washington , Jan. 20 BIO Ventures ... organizations are partnering to engage the global health community in using ... Pool.  The IP Pool was formed in February 2009 ... the treatment of 16 neglected tropical diseases, as defined by the ...
Cached Biology Technology:Scopus(R), TWOWS and TWAS Announce Young Women Researcher Award Recipients in Asia 2Scopus(R), TWOWS and TWAS Announce Young Women Researcher Award Recipients in Asia 3Scopus(R), TWOWS and TWAS Announce Young Women Researcher Award Recipients in Asia 4Scopus(R), TWOWS and TWAS Announce Young Women Researcher Award Recipients in Asia 5Scopus(R), TWOWS and TWAS Announce Young Women Researcher Award Recipients in Asia 6Scopus(R), TWOWS and TWAS Announce Young Women Researcher Award Recipients in Asia 7New treatment shown to reduce recurrence of debilitating diarrhea 2New treatment shown to reduce recurrence of debilitating diarrhea 3BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool 2BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool 3BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool 4
(Date:2/5/2015)... Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... ( http://www.nxt-id.com/ ) as part of its 2015 marketing ... Company launched its new consumer website for Wocketwallet.com earlier ... CEO of NXT-ID said, "Our new corporate website naturally ...
(Date:2/5/2015)... Conn. , Jan. 28, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... at the upcoming RedChip Global Online CEO Conference on ... Gino Pereira , CEO of NXT-ID ... its lead product, the Wocket smart wallet and its ...
(Date:2/5/2015)... 3, 2015 Despite a lack of ... such as consumer electronics, automotive, storage and telecommunication ... technology (SMT) screen printers. Innovations in electronics and ... push the adoption curve up. Meanwhile, sale volumes ... glue dispensers are indispensable in the production of ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... frogs around the world continue to disappearmany killed by ... skin cells of amphibiansone critically endangered species has received ... Hyloscirtus colymba , is notoriously difficult to care ... Project is the first to successfully breed this species. ...
... , , , , , , ... , , , ... improve the militarys ability to manage longleaf pine forests for carbon sequestration, productivity,... , ... , , , , , ...
... University of Arizona research indicates that leaf vein patterns ... use knowledge that could help scientists better understand ... of global climate warming. "Leaves have very different ... different thicknesses," said Benjamin Blonder, a doctoral student in ...
Cached Biology News:National Zoo and partners first to breed critically endangered tree frog 2Forest Service and partners to conduct longleaf pine-carbon research on military bases in 3 states 2Forest Service and partners to conduct longleaf pine-carbon research on military bases in 3 states 3Forest Service and partners to conduct longleaf pine-carbon research on military bases in 3 states 4Forest Service and partners to conduct longleaf pine-carbon research on military bases in 3 states 5Forest Service and partners to conduct longleaf pine-carbon research on military bases in 3 states 6The lifeblood of leaves: Vein networks control plant patterns 2The lifeblood of leaves: Vein networks control plant patterns 3
Mouse monoclonal [6G11] to Cytohesin 1 + 2 ( Abpromise for all tested applications)....
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Immunogen KLH-conjugated, ... acids 54-75 (RRGPHRNPG-PGDDDGQRSRSSS) of mouse ... mapped to amino acids 62-75. ... Routinely evaluated by immunoblot. ...
Request Info...
Biology Products: